Short Peptide Sequences for Antibacterial Ribosomal Tunnel Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rapid emergence of bacterial resistance to antibiotics necessitates the development of novel anti-infectives to effectively treat bacterial infections, particularly those caused by resistant strains like methicillin-resistant Staphylococcus aureus and vancomycin-resistant Staphylococcus aureus.
Innovation Solution
Administration of a therapeutically effective amount of a peptide comprising 3 to 5 amino acids, specifically sequences such as CMYW, CMY, GPP, MWC, PCQ, WMC, CKF, and others, which are selected for their antimicrobial properties and ability to target bacterial cells, potentially by blocking ribosomal exit tunnels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then bacterial growth is inhibited, but bacterial resistance emerges rapidly
Solution Approach 1:
The patent segments the antimicrobial function into multiple distinct peptide sequences (e.g., CMYW, CMY, GPP, MWC, PCQ, WMC, CKF) rather than relying on a single antibiotic compound. This segmentation allows the system to target bacteria through multiple mechanisms simultaneously, making it harder for bacteria to develop resistance to all peptides at once.
Solution Approach 2:
The invention employs composite peptide formulations combining sequences of different lengths (3-5 amino acids) and compositions. These composite peptide systems work synergistically to inhibit bacterial growth through multiple mechanisms including ribosomal exit tunnel blocking, membrane disruption, and protein synthesis inhibition, thereby overcoming single-antibiotic resistance.
2Reliability
If antibiotic treatment is applied to eliminate bacteria, then bacterial infection is controlled, but harmful side effects occur
Solution Approach 1:
The short peptide sequences (3-5 amino acids) are designed to interact specifically with local bacterial structures such as ribosomal exit tunnels and cell membrane regions. This localized targeting minimizes off-target effects on host cells while maintaining potent antimicrobial activity against the infection site.
Solution Approach 2:
The patent utilizes very short peptide sequences that are inherently less stable and more transient than conventional antibiotics. These short-lived peptides exert their antimicrobial effect rapidly and then degrade, reducing the accumulation of harmful residues and minimizing long-term side effects compared to persistent antibiotic compounds.
3Reliability
If new anti-infectives are developed to replace conventional antibiotics, then resistance emergence is slowed, but development complexity increases
Solution Approach 1:
The patent identifies universal antimicrobial patterns within the peptide sequences that can be applied across different bacterial strains and infection types. The core amino acid motifs (such as CMY, WMC, PCQ patterns) serve multiple functions including ribosomal binding, membrane interaction, and protein synthesis inhibition, reducing the need for entirely separate developments for different bacterial targets.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides demonstrate antimicrobial activity, effectively killing or inhibiting the growth of bacteria, including resistant strains, by targeting specific bacterial sequences, thereby providing an alternative or supplementary treatment option to conventional antibiotics.
Implementation Method 1
the isolated peptide is capable of blocking a ribosomal exit tunnel of a microorganism
Data Source
AI summary
A method of treating a bacterial infection in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a peptide being between 3 and 5 amino acids, wherein at least one amino acid of the 3 and 5 amino acids is selected from the group consisting of tryptophan, cysteine, proline and methionine.